Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

YS Biopharma Co., Ltd. YS NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • CN • USD

SharesGrow Score
28/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

YS Biopharma Co., Ltd. (YS) is a Biotechnology company in the Healthcare sector, currently trading at $1.02. It has a SharesGrow Score of 27/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $615M, +9.1%/yr average growth. Net income is $100M (loss), growing at -52.8%/yr. Net profit margin is -16.3% (negative). Gross margin is 82.5% (+5.8 pp trend).

Balance sheet: total debt is $414M against $500M equity (Debt-to-Equity (D/E) ratio 0.83, moderate). Current ratio is 1.02 (adequate). Debt-to-assets is 30.3%. Total assets: $1.4B.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 40/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 58/100 (Partial), Future ?/100 (Fail), Income 10/100 (Fail).

YS SharesGrow Score Overview

35/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 40/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 58/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — YS

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
40/100
YS: +9.1%/yr revenue is, -52.8%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet YS: Debt-to-Equity (D/E) ratio 0.83 (moderate), Current ratio is 1.02 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
58/100
YS: Gross margin is 82.5% (+5.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 58/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
YS: Net profit margin is -16.3%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.3503-1.78
Volume102.96K
Avg Volume (30D)130.56K
Market Cap$192.09M
Beta (1Y)0.54
Share Statistics
EPS (TTM)-0.94
Shares Outstanding$106.92M
IPO Date2021-08-05
Employees773
CEOHui Shao
Financial Highlights & Ratios
Revenue (TTM)$614.96M
Gross Profit$507.19M
EBITDA$-48.54M
Net Income$-99.98M
Operating Income$-86.29M
Total Cash$28.08M
Total Debt$414.4M
Net Debt$386.32M
Total Assets$1.37B
Price / Earnings (P/E)-1.1
Price / Sales (P/S)0.31
Analyst Forecast
Company Info
CountryCN
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINKYG9845F1090

Price Chart

Track all markets on TradingView
YS
YS Biopharma Co., Ltd. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.35 52WK RANGE 1.78

People Also View

IMMX
IMMX
Immix Biopharma, Inc.
$9.85
+1.65%
 ZURA
ZURA
Zura Bio Limited
$5.72
+0.70%
 ALLR
ALLR
Allarity Therapeutics, Inc.
$1.19
-0.76%
 SONN
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
-59.35%
 REVB
REVB
Revelation Biosciences, Inc.
$1.20
+0.84%
 QNRX
QNRX
Quoin Pharmaceuticals, Ltd.
$6.30
+6.42%
 CDIO
CDIO
Cardio Diagnostics Holdings, Inc.
$1.92
+2.13%
 ZVSA
ZVSA
ZyVersa Therapeutics, Inc.
$0.19
-8.57%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message